SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
REThinking lung cancer Chris Cain doi:10.1038/scibx.2012.219 Four research teams have independently identified a RET kinase fusion that could drive about 2% of lung adenocarcinoma cases. One of the groups hopes to begin a Phase II trial of Pfizer's multikinase inhibitor Sutent in RET fusion–positive patients in 1H12. In addition, Xcovery is looking for more specific RET inhibitors. Full Text | PDF
Personalized medicine triumvirate Michael J. Haas doi:10.1038/scibx.2012.220 Three Florida-based institutions are pooling resources in the Personalized Medicine Partnership of Florida to accelerate the discovery of markers that could predict individual responses to cancer, metabolic and cardiovascular therapies. Full Text | PDF
APOE in AD Tim Fulmer doi:10.1038/scibx.2012.221 U.S. researchers have shown that Eisai's cancer drug Targretin raises APOE levels in the brain and reverses cognitive and behavioral deficits in a mouse model of AD. The team has founded ReXceptor, which plans to start a proof-of-concept trial in about two months. Full Text | PDF
DNA nanorobots Lauren Martz doi:10.1038/scibx.2012.222 Researchers at Harvard University have designed drug delivery vehicles dubbed DNA nanorobots that enable the conditional delivery of therapeutic payloads based on the presence of combinations of markers on target cells. Next, the researchers need to optimize the nanorobots and scale up production. Full Text | PDF
IL-5 doi:10.1038/scibx.2012.223 Rat studies suggest IL-5 could help treat autoimmune diseases. Full Text | PDF
Receptor tyrosine kinase–like orphan receptor 2 (ROR2); wingless-type MMTV integration site family member 5A (WNT5A) doi:10.1038/scibx.2012.224 Mouse studies suggest inhibiting WNT5A-ROR2 signaling could help treat RA and RA-associated bone erosion. Full Text | PDF
Sulfatase 2 (SULF2) doi:10.1038/scibx.2012.225 Human tissue and mouse studies suggest antagonizing SULF2 could help treat glioblastoma multiforme (GBM). Full Text | PDF
MAP kinase kinase kinase 7 (MAP3K7; TAK1); K-Ras doi:10.1038/scibx.2012.226 Cell culture and mouse studies suggest inhibiting TAK1 could help treat K-Ras-dependent colon cancers. Full Text | PDF
Proprotein convertase subtilisin/kexin type 9 (PCSK9) doi:10.1038/scibx.2012.227 Mouse and nonhuman primate studies suggest an anti-PCSK9 antibody with pH-sensitive binding could treat hypercholesterolemia more effectively than non–pH-sensitive anti-PCSK9 antibodies. Full Text | PDF
Not applicable doi:10.1038/scibx.2012.228 Cell culture and mouse studies suggest the nitroimidazole compound fexinidazole could help treat leishmaniasis. Full Text | PDF
RSV F protein doi:10.1038/scibx.2012.229 In vitro studies suggest antibodies targeting the prefusion conformation of the RSV F protein could be a more efficient alternative to current RSV prophylactics. Full Text | PDF
Crystallin αB (CRYAB; HSPB5) doi:10.1038/scibx.2012.230 In vitro studies identified a mechanism for HSPB5's anti-inflammatory activity that could help improve treatment of multiple sclerosis (MS). Full Text | PDF
Lipin 2 (LPIN2) doi:10.1038/scibx.2012.231 Cell culture studies suggest increasing LPIN2 activity could help prevent fatty acid–induced inflammation, which has been linked to diseases including type 2 diabetes. Full Text | PDF
Dysferlin (DYSF); proteasome doi:10.1038/scibx.2012.232 Cell culture studies suggest inhibiting proteasome-mediated degradation of DYSF could help treat muscular dystrophy. Full Text | PDF
Retinoid X receptor (RXR) doi:10.1038/scibx.2012.233 Mouse studies suggest agonizing RXR in the brain could help treat AD. Full Text | PDF
Discs large homolog 4 (DLG4; PSD95) doi:10.1038/scibx.2012.234 Mouse studies identified a peptide-based PSD95 inhibitor that could help treat stroke. Full Text | PDF
RNA sequencing of multiple drug-resistant cells to identify therapeutic targets and mechanisms of action doi:10.1038/scibx.2012.235 In vitro studies suggest RNA sequencing of drug-resistant cells could help identify a compound's therapeutic target. Full Text | PDF
Cellular model for Alzheimer's disease (AD) based on induced pluripotent stem (iPS) cells and embryonic stem cells (ESCs) from patients with Down syndrome doi:10.1038/scibx.2012.236 A cellular model for AD in Down syndrome could help identify mechanisms of AD and test AD therapeutics. Full Text | PDF
Inducible mouse model of ovarian cancer doi:10.1038/scibx.2012.237 Mice with inducible ablation of p53 and activation of K-Ras in the ovary and/or oviduct could aid the development of new treatments for ovarian cancer. Full Text | PDF
Mouse model of Epstein-Barr virus (EBV)-driven B cell lymphoma doi:10.1038/scibx.2012.238 Mice that express EBV latent membrane protein 1 (Lmp-1) in B cells could aid the development of new treatments for EBV-associated lymphoma. Full Text | PDF
Mouse model of serous ovarian cancer doi:10.1038/scibx.2012.239 A mouse model of high-grade serous ovarian cancer could help identify biomarkers or therapeutics to treat the disease. Full Text | PDF
Chemical and structural profiling of poly(ADP-ribose) polymerase (PARP) inhibitor selectivity doi:10.1038/scibx.2012.240 Chemical and structural profiling of PARP inhibitors could help identify strategies for designing more selective inhibitors. Full Text | PDF
Crystal structures to guide the design of immunoproteasome-specific inhibitors doi:10.1038/scibx.2012.241 Crystal structures of constitutive proteasomes and immunoproteasomes could guide the design of immunoproteasome-specific inhibitors. Full Text | PDF
Phosphorylated α-synuclein (SNCA) as a marker for diagnosing and monitoring progression in Parkinson's disease (PD) doi:10.1038/scibx.2012.242 Patient sample studies suggest measuring phosphorylated SNCA levels could help diagnose and monitor PD. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment